Bank of New York Mellon Corp - KINNATE BIOPHARMA INC ownership

KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 73 filers reported holding KINNATE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of KINNATE BIOPHARMA INC
ValueSharesWeighting
Q1 2023$611,338
+1.2%
97,814
-1.2%
0.00%
Q4 2022$603,968
-48.1%
99,011
+1.7%
0.00%
Q3 2022$1,163,000
+4.1%
97,321
+9.9%
0.00%
Q2 2022$1,117,000
+6.7%
88,529
-4.8%
0.00%
Q1 2022$1,047,000
-37.4%
93,021
-1.4%
0.00%
Q4 2021$1,672,000
+8.4%
94,338
+40.8%
0.00%
Q3 2021$1,543,000
+62.8%
66,990
+64.5%
0.00%
Q2 2021$948,000
-15.0%
40,723
+13.9%
0.00%
Q1 2021$1,115,00035,7660.00%
Other shareholders
KINNATE BIOPHARMA INC shareholders Q4 2021
NameSharesValueWeighting ↓
Foresite Capital Management IV, LLC 9,671,643$225,156,00030.44%
Vida Ventures Advisors, LLC 2,747,433$63,960,00016.04%
Foresite Capital Management V, LLC 875,001$20,370,0008.01%
VR Adviser, LLC 1,473,014$34,292,0004.16%
Logos Global Management LP 1,329,602$30,953,0002.60%
RA Capital Management 3,593,052$83,646,0001.34%
Orbimed Advisors 3,847,929$89,580,0000.91%
Boxer Capital, LLC 1,065,939$24,815,0000.88%
HARVARD MANAGEMENT CO INC 498,001$11,593,0000.67%
HighVista Strategies LLC 33,391$777,0000.55%
View complete list of KINNATE BIOPHARMA INC shareholders